skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

16 Total results for product and free and sample content found

Pink Sheet

Trumps Drug Pricing Plan: The Headlines Are The Goal - But Also A Threat

By Michael McCaughan 16 Jun 2022

US Election Drug Pricing Reform

The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.

Topic US Election 2020

Medtech Insight

US Election 2020: Almost All House Members Backed By Industry PAC Dollars Retain Seats

By Sue Darcey 16 Jun 2022

US Election 2020 PAC dollars

Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.

Topic US Election 2020 Policy & Regulation Legislation

Medtech Insight

US Election 2020: Industry Loses Three Favored Incumbents In Battle For Senate Control

By Sue Darcey 18 Nov 2020

US Election senate battle

A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election

Topic US Election 2020 Legislation

Pink Sheet

Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly

By Cathy Kelly 18 Nov 2020

Biden Administration Rx Pricing

A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry

Topic US Election 2020 Drug Pricing

Pink Sheet

Biden, Germany And Bringing A National Drug Pricing Negotiation Process To US

By Cathy Kelly 17 Nov 2020

Biden US Election 2020 final debate

Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.

Topic US Election 2020 Drug Pricing

Pink Sheet

Pfizer's COVID-19 Vaccine Will Miss US Election, Bourla Clarifies

By Joseph Haas 29 Oct 2020

Pfizer CEO Albert Bourla

EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least

Topic US Election 2020 Vaccines Coronavirus

Pink Sheet

Regeneron Pushes Legal, Ethical Boundaries With Offer Of COVID-19 Antibody To Biden Campaign

By Sarah Karlin-Smith 21 Oct 2020

Pink Sheet Regeneron Biden Campaign Coronavirus

Company may have violated FDA’s preapproval promotion restrictions by discussing compassionate use option with Joe Biden’s team and by publicizing it on TV, highlighting the fine line between making the general public aware of expanded access and touting an investigational product as useful for a particular illness.

Topic Coronavirus Advertising, Marketing & Sales US Election 2020

Pink Sheet, Scrip

Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire

By Sarah Karlin-Smith 09 Oct 2020

Trump Supporters at Walter Reed Hospital

Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.

Topic Coronavirus US Election 2020 Clinical Trials

Generics Bulletin

AAM Ramps Up US Election Lobbying

By Akriti Seth 25 Sep 2020

US Elections AAM Generics

The AAM has published a timely guide highlighting various voter issues of concern in the run-up to the US elections, including anti-competitive tactics building on monopoly pricing and weak patent laws. The AAM has also called for policies to encourage generic and biosimilar entry in the market while the guide also focuses on policies around the US supply chain.

Topic US Election 2020 Policy & Regulation

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: